Details of the Drug

General Information of Drug (ID: DMNKG1Z)

Drug Name

Atenolol

Synonyms

Aircrit; Alinor; Altol; Anselol; Antipressan; Atcardil; Atecard; Atehexal; Atenblock; Atendol; Atenet; Ateni; Atenil; Atenol; Atenolin; Atenololum; Atenomel; Atereal; Aterol; Betablok; Betacard; Betasyn; Blocotenol; Blokium; Cardaxen; Cardiopress; Corotenol; Cuxanorm; Duraatenolol; Duratenol; Evitocor; Farnormin; Hipres; Hypoten; Ibinolo; Internolol; Jenatenol; Juvental; Loten; Lotenal; Myocord; Neatenol; Normalol; Normiten; Noten; Oraday; Ormidol; Panapres; Plenacor; Premorine; Prenolol; Prenormine; Prinorm; Selobloc; Serten; Servitenol; Stermin; Tenidon; Tenobloc; Tenoblock; Tenolol; Tenoprin; Tenormin; Tenormine; Tensimin; Tensotin; Tredol; Unibloc; Uniloc; Vascoten; Vericordin; Wesipin; Xaten; Atenol AL; Atenol Atid; Atenol Cophar; Atenol Fecofar; Atenol GNR; Atenol Gador; Atenol Genericon; Atenol Heumann; Atenol MSD; Atenol NM Pharma; Atenol Nordic; Atenol PB; Atenol Quesada; Atenol Stada; Atenol Tika; Atenol Trom; Atenol acis; Atenol ct; Atenol von ct; Betatop Ge; Scheinpharm Atenol; Seles beta; Tenormine [French]; A 7655; Atenol 1A pharma; Apo-Atenolol; Atenol-Mepha; Atenol-Wolff; Atenol-ratiopharm; Atenololum [INN-Latin]; Felo-Bits; Lo-ten; Teno-basan; Tenormin (TN); Atenolol (JP15/USP/INN); Atenolol [USAN:INN:BAN:JAN]; Acetamide,2-(p-(2-hydroxy-3-(isopropylamino)propoxy)phenyl); (+-)-4-(2-Hydroxy-3-isopropylaminopropoxy)phenylacetamide; (+-)-Atenolol; (+/-)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide; (1)-2-(4-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide; (inverted question mark)-Atenolol; 1-p-Carbamoylmethylphenoxy-3-isopropylamino-2-propanol; 2-(4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl)acetamid; 2-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)acetamide; 2-(p-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide; 2-[4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl]acetamide; 2-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]acetamide; 2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide; 2-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide; 4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide; 4-[2'-Hydroxy-3'-(isopropylamino)propoxy]phenylacetamide; 4-[2-Hydroxy-3-(isopropylamino)-propoxy]phenylacetamide

Indication

Disease Entry	ICD 11	Status	REF
Angina pectoris	BA40	Approved	[1]
Hypertension	BA00-BA04	Approved	[2]
Malignant essential hypertension	BA00	Approved	[1]
Myocardial infarction	BA41-BA43	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Antihypertensive Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

266.34

Logarithm of the Partition Coefficient (xlogp)

0.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Bioavailability: 56% of drug becomes completely available to its intended biological destination(s) [4]
Clearance: The renal clearance of drug is 95-168 mL/min [5]
Elimination: 94% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 6 - 7 hours [6]
Metabolism: The drug is metabolized via the liver [7]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 12.50267 micromolar/kg/day [8]
Unbound Fraction: The unbound fraction of drug in plasma is 0.94% [6]
Vd: The volume of distribution (Vd) of drug is 63.8-112.5 L [5]
Water Solubility: The ability of drug to dissolve in water is measured as 24.8 mg/mL [3]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Adverse drug reaction	Not Available	CYP2D6	OTZJC802	[9]
Sudden cardiac death	Not Available	SCN5A	OTGYZWR6	[9]
Sudden cardiac death	Not Available	KCNE1	OTZNQUW9	[9]
Sudden cardiac death	Not Available	KCNH2	OTZX881H	[9]
-----------

Chemical Identifiers

Formula: C14H22N2O3
IUPAC Name: 2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide
Canonical SMILES: CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O
InChI: InChI=1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)
InChIKey: METKIMKYRPQLGS-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 2249
ChEBI ID: CHEBI:2904
CAS Number: 29122-68-7
DrugBank ID: DB00335
TTD ID: D01UXC
VARIDT ID: DR00033
INTEDE ID: DR0617
ACDINA ID: D00048

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor beta-1 (ADRB1)	TTR6W5O	ADRB1_HUMAN	Antagonist	[10]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[11]
Organic anion transporting polypeptide 1A2 (SLCO1A2)	DTE2B1D	SO1A2_HUMAN	Substrate	[12]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[13]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[14]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[15]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Alpha-2A adrenergic receptor (ADRA2A)	OTZFGOTP	ADA2A_HUMAN	Drug Response	[16]
Angiotensinogen (AGT)	OTBZLYR3	ANGT_HUMAN	Gene/Protein Processing	[17]
Apolipoprotein A-I (APOA1)	OT5THARI	APOA1_HUMAN	Gene/Protein Processing	[18]
Apolipoprotein A-II (APOA2)	OTQ3HGTC	APOA2_HUMAN	Gene/Protein Processing	[18]
Apolipoprotein B-100 (APOB)	OTH0UOCZ	APOB_HUMAN	Gene/Protein Processing	[18]
B2 bradykinin receptor (BDKRB2)	OTOA9D3W	BKRB2_HUMAN	Drug Response	[19]
Beta-2 adrenergic receptor (ADRB2)	OTSDOX4Q	ADRB2_HUMAN	Gene/Protein Processing	[20]
Beta-2-microglobulin (B2M)	OTDWN6NX	B2MG_HUMAN	Gene/Protein Processing	[21]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Gene/Protein Processing	[22]
C-type lectin domain family 2 member B (CLEC2B)	OT0W0M0L	CLC2B_HUMAN	Gene/Protein Processing	[23]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Atenolol

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Levamlodipine	DM92S6N	Moderate	Increased risk of cardiac depression by the combination of Atenolol and Levamlodipine.	Hypertension [BA00-BA04]	[24]
Verapamil	DMA7PEW	Major	Increased risk of cardiac depression by the combination of Atenolol and Verapamil.	Hypertension [BA00-BA04]	[24]
Diltiazem	DMAI7ZV	Major	Increased risk of cardiac depression by the combination of Atenolol and Diltiazem.	Hypertension [BA00-BA04]	[24]
Amlodipine	DMBDAZV	Moderate	Increased risk of cardiac depression by the combination of Atenolol and Amlodipine.	Hypertension [BA00-BA04]	[24]
Indapamide	DMGN1PW	Moderate	Increased risk of hyperglycemia by the combination of Atenolol and Indapamide.	Hypertension [BA00-BA04]	[25]
Trichlormethiazide	DMHAQCO	Moderate	Increased risk of ventricular arrhythmias by the combination of Atenolol and Trichlormethiazide.	Hypertension [BA00-BA04]	[25]
Felodipine	DMOSW35	Moderate	Increased risk of cardiac depression by the combination of Atenolol and Felodipine.	Hypertension [BA00-BA04]	[24]
Hydrochlorothiazide	DMUSZHD	Moderate	Increased risk of ventricular arrhythmias by the combination of Atenolol and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[25]
Clevidipine butyrate	DMW4M97	Moderate	Increased risk of cardiac depression by the combination of Atenolol and Clevidipine butyrate.	Hypertension [BA00-BA04]	[24]
-----------


⏷ Show the Full List of 9 DDI Information of This Drug

Coadministration of a Drug Treating the Disease Different from Atenolol (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sucralfate	DMP9HBO	Minor	Decreased absorption of Atenolol due to formation of complexes caused by Sucralfate.	Acne vulgaris [ED80]	[26]
Dronedarone	DMA8FS5	Moderate	Increased risk of bradycardia by the combination of Atenolol and Dronedarone.	Angina pectoris [BA40]	[27]
Nifedipine	DMSVOZT	Moderate	Increased risk of cardiac depression by the combination of Atenolol and Nifedipine.	Angina pectoris [BA40]	[24]
Promazine	DMZAL7W	Moderate	Additive hypotensive effects by the combination of Atenolol and Promazine.	Appearance/behaviour symptom [MB23]	[28]
Ampicillin	DMHWE7P	Moderate	Altered absorption of Atenolol caused by Ampicillin.	Bacterial infection [1A00-1C4Z]	[29]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Atenolol and Cariprazine.	Bipolar disorder [6A60]	[28]
Atracurium	DM42HXN	Moderate	Additive neuromuscular blocking effects by the combination of Atenolol and Atracurium.	Corneal disease [9A76-9A78]	[30]
Mivacurium	DM473VD	Moderate	Additive neuromuscular blocking effects by the combination of Atenolol and Mivacurium.	Corneal disease [9A76-9A78]	[30]
Pancuronium	DMB0VY8	Moderate	Additive neuromuscular blocking effects by the combination of Atenolol and Pancuronium.	Corneal disease [9A76-9A78]	[30]
Tubocurarine	DMBZIVP	Moderate	Additive neuromuscular blocking effects by the combination of Atenolol and Tubocurarine.	Corneal disease [9A76-9A78]	[30]
Nimodipine	DMQ0RKZ	Moderate	Increased risk of cardiac depression by the combination of Atenolol and Nimodipine.	Coronary vasospastic disease [BA85]	[24]
Pasireotide	DMHM7JS	Moderate	Increased risk of atrioventricular block by the combination of Atenolol and Pasireotide.	Cushing syndrome [5A70]	[31]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Atenolol and OPC-34712.	Depression [6A70-6A7Z]	[28]
Hyoscyamine	DM804UR	Moderate	Antagonize the effect of Atenolol when combined with Hyoscyamine.	Digestive system disease [DE2Z]	[32]
Mepenzolate	DM8YU2F	Moderate	Antagonize the effect of Atenolol when combined with Mepenzolate.	Digestive system disease [DE2Z]	[32]
Oxybutynine	DMJPBAX	Moderate	Antagonize the effect of Atenolol when combined with Oxybutynine.	Discovery agent [N.A.]	[32]
Trihexyphenidyl	DMB19L8	Moderate	Antagonize the effect of Atenolol when combined with Trihexyphenidyl.	Dystonic disorder [8A02]	[32]
Ethacrynic acid	DM60QMR	Moderate	Increased risk of hyperglycemia by the combination of Atenolol and Ethacrynic acid.	Essential hypertension [BA00]	[25]
Bendroflumethiazide	DM7EVLC	Moderate	Increased risk of ventricular arrhythmias by the combination of Atenolol and Bendroflumethiazide.	Essential hypertension [BA00]	[25]
Phenoxybenzamine	DM8KSQH	Moderate	Additive hypotensive effects by the combination of Atenolol and Phenoxybenzamine.	Essential hypertension [BA00]	[33]
Nicardipine	DMCDYW7	Moderate	Increased risk of cardiac depression by the combination of Atenolol and Nicardipine.	Essential hypertension [BA00]	[24]
Benzthiazide	DMQWZ0H	Moderate	Increased risk of hyperglycemia by the combination of Atenolol and Benzthiazide.	Essential hypertension [BA00]	[25]
Phenylephrine	DMZHUO5	Moderate	Additive hypertensive effects by the combination of Atenolol and Phenylephrine.	Faecal incontinence [ME07]	[34]
Tolterodine	DMSHPW8	Moderate	Antagonize the effect of Atenolol when combined with Tolterodine.	Functional bladder disorder [GC50]	[32]
Propantheline	DM2EN6G	Moderate	Antagonize the effect of Atenolol when combined with Propantheline.	Gastric ulcer [DA60]	[32]
Cimetidine	DMH61ZB	Moderate	Decreased metabolism of Atenolol caused by Cimetidine mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[35]
Spironolactone	DM2AQ5N	Moderate	Increased risk of ventricular arrhythmias by the combination of Atenolol and Spironolactone.	Heart failure [BD10-BD1Z]	[25]
Triamterene	DM2HU9I	Moderate	Increased risk of ventricular arrhythmias by the combination of Atenolol and Triamterene.	Heart failure [BD10-BD1Z]	[25]
Prazosin	DMCD9YG	Moderate	Additive hypotensive effects by the combination of Atenolol and Prazosin.	Heart failure [BD10-BD1Z]	[33]
Chlorothiazide	DMLHESP	Moderate	Increased risk of ventricular arrhythmias by the combination of Atenolol and Chlorothiazide.	Heart failure [BD10-BD1Z]	[25]
Furosemide	DMMQ8ZG	Moderate	Increased risk of ventricular arrhythmias by the combination of Atenolol and Furosemide.	Heart failure [BD10-BD1Z]	[25]
Bumetanide	DMRV7H0	Moderate	Increased risk of hypertriglyceridemia by the combination of Atenolol and Bumetanide.	Heart failure [BD10-BD1Z]	[25]
Hydroflumethiazide	DMVPUQI	Moderate	Increased risk of hypertriglyceridemia by the combination of Atenolol and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[25]
Belladonna	DM2RBWK	Moderate	Antagonize the effect of Atenolol when combined with Belladonna.	Infectious gastroenteritis/colitis [1A40]	[32]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Atenolol and ITI-007.	Insomnia [7A00-7A0Z]	[28]
Clidinium	DMUMQZ0	Moderate	Antagonize the effect of Atenolol when combined with Clidinium.	Irritable bowel syndrome [DD91]	[32]
Dicyclomine	DMZSDGX	Moderate	Antagonize the effect of Atenolol when combined with Dicyclomine.	Irritable bowel syndrome [DD91]	[32]
Lanthanum carbonate	DMMJQSH	Moderate	Decreased absorption of Atenolol due to formation of complexes caused by Lanthanum carbonate.	Mineral absorption/transport disorder [5C64]	[31]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Atenolol and Thalidomide.	Multiple myeloma [2A83]	[36]
Siponimod	DM2R86O	Major	Increased risk of atrioventricular block by the combination of Atenolol and Siponimod.	Multiple sclerosis [8A40]	[36]
Fingolimod	DM5JVAN	Major	Increased risk of bradycardia by the combination of Atenolol and Fingolimod.	Multiple sclerosis [8A40]	[37]
Ozanimod	DMT6AM2	Moderate	Increased risk of atrioventricular block by the combination of Atenolol and Ozanimod.	Multiple sclerosis [8A40]	[38]
Prochlorperazine	DM53SRA	Moderate	Additive hypotensive effects by the combination of Atenolol and Prochlorperazine.	Nausea/vomiting [MD90]	[28]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Atenolol and Promethazine.	Nausea/vomiting [MD90]	[28]
Thiethylperazine	DMU3IET	Moderate	Additive hypotensive effects by the combination of Atenolol and Thiethylperazine.	Nausea/vomiting [MD90]	[28]
Metolazone	DMB39LO	Moderate	Increased risk of hypertriglyceridemia by the combination of Atenolol and Metolazone.	Oedema [MG29]	[25]
Polythiazide	DMCH80F	Moderate	Increased risk of ventricular arrhythmias by the combination of Atenolol and Polythiazide.	Oedema [MG29]	[25]
Procyclidine	DMHFJDT	Moderate	Antagonize the effect of Atenolol when combined with Procyclidine.	Parkinsonism [8A00]	[32]
Methylscopolamine	DM5VWOB	Moderate	Antagonize the effect of Atenolol when combined with Methylscopolamine.	Peptic ulcer [DA61]	[32]
Terazosin	DM3JCVS	Moderate	Additive hypotensive effects by the combination of Atenolol and Terazosin.	Prostate hyperplasia [GA90]	[33]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Atenolol and Silodosin.	Prostate hyperplasia [GA90]	[33]
Alfuzosin	DMZVMKF	Moderate	Additive hypotensive effects by the combination of Atenolol and Alfuzosin.	Prostate hyperplasia [GA90]	[33]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Atenolol and Levomepromazine.	Psychotic disorder [6A20-6A25]	[28]
Fluphenazine	DMIT8LX	Moderate	Additive hypotensive effects by the combination of Atenolol and Fluphenazine.	Psychotic disorder [6A20-6A25]	[28]
Triflupromazine	DMKFQJP	Moderate	Additive hypotensive effects by the combination of Atenolol and Triflupromazine.	Psychotic disorder [6A20-6A25]	[28]
Mesoridazine	DM2ZGAN	Moderate	Additive hypotensive effects by the combination of Atenolol and Mesoridazine.	Schizophrenia [6A20]	[28]
Thioridazine	DM35M8J	Moderate	Additive hypotensive effects by the combination of Atenolol and Thioridazine.	Schizophrenia [6A20]	[28]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Atenolol and Aripiprazole.	Schizophrenia [6A20]	[28]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Atenolol and Iloperidone.	Schizophrenia [6A20]	[28]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Atenolol and Paliperidone.	Schizophrenia [6A20]	[28]
Loxapine	DM8AI9U	Moderate	Additive hypotensive effects by the combination of Atenolol and Loxapine.	Schizophrenia [6A20]	[28]
Haloperidol	DM96SE0	Moderate	Additive hypotensive effects by the combination of Atenolol and Haloperidol.	Schizophrenia [6A20]	[28]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Atenolol and Molindone.	Schizophrenia [6A20]	[28]
Chlorpromazine	DMBGZI3	Moderate	Additive hypotensive effects by the combination of Atenolol and Chlorpromazine.	Schizophrenia [6A20]	[28]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Atenolol and Thiothixene.	Schizophrenia [6A20]	[28]
Trifluoperazine	DMKBYWI	Moderate	Additive hypotensive effects by the combination of Atenolol and Trifluoperazine.	Schizophrenia [6A20]	[28]
Risperidone	DMN6DXL	Moderate	Additive hypotensive effects by the combination of Atenolol and Risperidone.	Schizophrenia [6A20]	[28]
Amisulpride	DMSJVAM	Moderate	Increased risk of ventricular arrhythmias by the combination of Atenolol and Amisulpride.	Schizophrenia [6A20]	[32]
Pipecuronium	DM5F84A	Moderate	Additive cardiorespiratory depression effects by the combination of Atenolol and Pipecuronium.	Tonus and reflex abnormality [MB47]	[30]
Doxacurium	DMKE7L9	Moderate	Additive neuromuscular blocking effects by the combination of Atenolol and Doxacurium.	Tonus and reflex abnormality [MB47]	[30]
Vecuronium	DMP0UK2	Moderate	Additive neuromuscular blocking effects by the combination of Atenolol and Vecuronium.	Tonus and reflex abnormality [MB47]	[30]
Cisatracurium	DMUZPJ5	Moderate	Additive neuromuscular blocking effects by the combination of Atenolol and Cisatracurium.	Tonus and reflex abnormality [MB47]	[30]
Rocuronium	DMY9BMK	Moderate	Additive neuromuscular blocking effects by the combination of Atenolol and Rocuronium.	Tonus and reflex abnormality [MB47]	[30]
Atropine	DMEN6X7	Moderate	Antagonize the effect of Atenolol when combined with Atropine.	Unspecific substance harmful effect [NE6Z]	[32]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Atenolol and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[28]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Atenolol and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[39]
Amiodarone	DMUTEX3	Moderate	Increased risk of bradycardia by the combination of Atenolol and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[40]
-----------


⏷ Show the Full List of 77 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Glycerin	E00026	753	Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Magnesium carbonate	E00205	11029	Adsorbent; Diluent
Magnesium stearate	E00208	11177	lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 12 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Atenolol 100 mg tablet	100 mg	Oral Tablet	Oral
Atenolol 25 mg tablet	25 mg	Oral Tablet	Oral
Atenolol 50 mg tablet	50 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Atenolol FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 548).
3	BDDCS applied to over 900 drugs
4	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5	Kirch W, Gorg KG: Clinical pharmacokinetics of atenolol--a review. Eur J Drug Metab Pharmacokinet. 1982;7(2):81-91. doi: 10.1007/BF03188723.
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	Kharasch ED, Thummel KE: Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology. 1993 Oct;79(4):795-807.
8	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
10	Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6.
11	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
12	Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol. 2010 Nov;70(5):645-55.
13	Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500.
14	Metabolism of atenolol in man. Xenobiotica. 1978 May;8(5):313-20.
15	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
16	Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment. J Hypertens. 2004 Dec;22(12):2321-8. doi: 10.1097/00004872-200412000-00014.
17	Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). J Cardiovasc Pharmacol. 2003 Dec;42(6):719-26. doi: 10.1097/00005344-200312000-00005.
18	The effects of clonidine hydrochloride versus atenolol monotherapy on serum lipids, lipid subfractions, and apolipoproteins in mild hypertension. Am Heart J. 1990 Jul;120(1):172-9. doi: 10.1016/0002-8703(90)90175-w.
19	B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J Hypertens. 2003 Mar;21(3):621-4. doi: 10.1097/00004872-200303000-00029.
20	Atenolol-induced regulation of leukocyte beta 2-adrenoceptors in hypertension. Pharmacology. 1984;29(4):210-4. doi: 10.1159/000138015.
21	A 1-year follow-up study on the effect of atenolol on serum beta 2-microglobulin level in hypertensive diabetic patients. J Int Med Res. 1989 Mar-Apr;17(2):162-7. doi: 10.1177/030006058901700208.
22	Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
23	Change in mRNA Expression after Atenolol, a Beta-adrenergic Receptor Antagonist and Association with Pharmacological Response. Arch Drug Inf. 2009 Sep;2(3):41-50. doi: 10.1111/j.1753-5174.2009.00020.x.
24	Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167]
25	Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA "Nadolol in combination with indapamide and xipamide in resistant hypertensives." Eur J Clin Pharmacol 28 (1985): 29-33. [PMID: 3987783]
26	D'Arcy PF, McElnay JC "Drug-antacid interactions: assessment of clinical importance." Drug Intell Clin Pharm 21 (1987): 607-17. [PMID: 2886325]
27	Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
28	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
29	McLean AJ, Tonkin A, McCarthy P, Harrison P "Dose-dependence of atenolol-ampicillin interaction." Br J Clin Pharmacol 18 (1984): 969-71. [PMID: 6529538]
30	Chapple DJ, Clark JS, Hughes R "Interaction between atracurium and drugs used in anaesthesia." Br J Anaesth 55 Suppl 1 (1983): s17-22. [PMID: 6688011]
31	Canadian Pharmacists Association.
32	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
33	Chrysant SG "Experience with terazosin administered in combination with other antihypertensive agents." Am J Med 80 (1986): 55-61. [PMID: 2872808]
34	Cass E, Kadar D, Stein HA "Hazards of phenylephrine topical medication in persons taking propranolol." Can Med Assoc J 120 (1979): 1261-2. [PMID: 221086]
35	Asgharnejad M, Powell R, Donn K, Danis M "The effect of cimetidine dose timing on oral propranolol kinetics in adults." Clin Pharmacol Ther 41 (1987): 203. [PMID: 3392231]
36	Cerner Multum, Inc. "Australian Product Information.".
37	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
38	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
39	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
40	Leor J, Levartowsky D, Sharon C, Farfel Z "Amiodarone and beta-adrenergic blockers: an interaction with metoprolol but not with atenolol." Am Heart J 16 (1988): 206-7. [PMID: 3394625]